Navigation Links
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
Date:5/31/2008

(20%) of patients experienced at least 1 episode of >/= Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). Adverse events thought by the investigator to be drug-related and leading to discontinuation occurred in 22% of patients. The reasons for discontinuation included peripheral neuropathy (8%), asthenic conditions (3%) and thrombocytopenia and diarrhea (each 2%). In total, 2% of the patients died and the cause of death was considered by the investigator to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Additional information about Millennium is available through its website, http://www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important r
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... England , July 2, 2015 ... known as ,Friendly Aedes aegypti , , ... Juazeiro, Brazil by 95%, well ...      (Logo: http://photos.prnewswire.com/prnh/20150630/227348LOGO) , The journal ... a trial of Oxitec,s genetically engineered mosquitoes. The results ...
(Date:7/2/2015)... 2015 According to a new market ... Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, ... 2020", published by MarketsandMarkets, the global Neuromodulation Market is estimated ... $6.20 Billion by 2020, at a CAGR of 11.2% during ... 4 market data T ables and ...
(Date:7/2/2015)... June 25, 2015 Research and Markets( ... Market by Technology, Imaging and by Application - Forecast to 2020" ... market is expected to reach $13.1 Billion in 2020 from an ... The market is dominated by North America ... Asia , and Rest of the World (RoW). The cancer ...
Breaking Medicine Technology:Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Global Cancer Diagnostics Market Report 2015 - Technology, Imaging and by Applications Forecasts to 2020 for the $13 Billion Industry 2
... , April 26 Body ... for the Apple iPhone, is now available on the new iPad ... of its kind to help people live healthier lifestyles by showing ... things can help them eat better, sleep better and handle stress ...
... TAMPA, Fla. , April 26 Sirion ... that Zirgan™ (ganciclovir ophthalmic gel) 0.15% is now commercially available. ... Administration in September 2009 , is a topical ophthalmic ... ulcers).   , , ...
Cached Medicine Technology:Heal Your 'Body & Mind' on the iPad, Too! 2Heal Your 'Body & Mind' on the iPad, Too! 3Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 2Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 3
(Date:7/4/2015)... ... 04, 2015 , ... Tyler Boden, Project Developer of Sullivan ... from the North American Board of Certified Energy Practitioners (NABCEP®), and is now ... and well established national certification organization for renewable energy professionals. Designation as a ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... Scientists at ... susceptible to mesothelioma with even minimal asbestos exposure. Click here to read the ... the University of Hawaii Cancer Center, Cedars Sinai Medical Center, and New York University ...
(Date:7/3/2015)... Orange, CT (PRWEB) , ... July 03, 2015 , ... ... at home is a good blender and easily accessible, quality ingredients. Aurora Natural is ... your smoothie for an added boost of fiber, protein, antioxidants, vitamins and minerals! , ...
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The ... he says will reveal biblical truth and expose popular lies regarding proper relationships according ... Don’t Have Sex”, immediately goes into the core of the subject by explaining why ...
(Date:7/2/2015)... , ... July 02, 2015 , ... sweetFrog Enterprises, LLC. ... opening is now the 19th sweetFrog store located in the Lone Star State. The ... fastest growing companies in 2014. , The store, which opened July 1 at Duke’s ...
Breaking Medicine News(10 mins):Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2
... , , , , , ... , , AUDIO: ... cancer... , Click here for more information. , ... , , , , , ...
... that looked at the hunger trends over a 10-year period ... more than one in seven, face the threat of hunger. ... reported that one in nine seniors faced the threat of ... agricultural and consumer economics and executive director of the National ...
... HealthDay Reporter , MONDAY, May 14 (HealthDay News) ... less likely to continue their education or get a job ... disabilities, new research indicates. According to the study, only ... and only 55 percent had a job during the first ...
... May 14 (HealthDay News) -- The multiple sclerosis drug ... certain pre-existing or recent heart conditions or stroke, or ... says a U.S. Food and Drug Administration safety announcement ... of a report of a patient who died within ...
... (San Antonio)Nice guys do finish last at least when it ... of Texas at San Antonio that answers the question of ... assistant professor of marketing at The University of Texas at ... with ovulation influence women,s perceptions of men as potential fathers. ...
... has identified microRNA-3151 as a new independent prognostic marker ... patients with acute myeloid leukemia and normal-looking chromosomes ,(CN-AML). ... University Comprehensive Cancer Center Arthur G. James Cancer ... James) found that when microRNA-3151 (miR-3151) is overexpressed in ...
Cached Medicine News:Health News:Genetic test identifies eye cancer tumors likely to spread 2Health News:Genetic test identifies eye cancer tumors likely to spread 3Health News:Genetic test identifies eye cancer tumors likely to spread 4Health News:Genetic test identifies eye cancer tumors likely to spread 5Health News:Great recession reflux amounts to more hunger among seniors 2Health News:Employment Prospects Dim for Young Adults With Autism 2Health News:Employment Prospects Dim for Young Adults With Autism 3Health News:FDA Issues Multiple Sclerosis Drug Alert 2Health News:UTSA study finds ovulating women perceive sexy cads as good dads 2Health News:A microRNA prognostic marker identified in acute leukemia 2
... 2200 system is a fully automated ... deliver up to 2200 results per ... a panel of assays targeting autoimmune ... in the areas of serology, infectious ...
... ASR contains primers and a FAM-labeled probe targeting ... as well as primers and an Alexa 532-labeled ... of HSV Type 2. This ASR requires an ... Alexa reporter dyes like the Cepheid SmartCycler System. ...
... The HSV Non-Typing ASR contains primers and a ... 92 bp region of the HSV Type 1 ... an instrument that can detect a FAM reporter ... Cepheid Analyte Specific Reagent* (ASR) program is comprised ...
... Stratus CS Analyzer, designed for Acute Care Diagnostics, ... laboratory and near patient setting. It's a random ... D-Dimer results from a whole blood sample in ... step process load sample and rotor, load ...
Medicine Products: